ALSO NOTED: Caraco gets FDA nod for GSK seizure drug; Mylan prices offering of stock;

> Caraco Pharmaceutical got tentative FDA approval for its copycat form of GlaxoSmithKline's Lamictal, a remedy for seizures and bipolar episodes that sold some $1.89 billion in the 12 months ended Sept. 30. Release

> Mylan announced that it has priced its new offering of preferred stock at $1,000 per share and common stock at $14 per share; the company intends to sell 1.86 million shares of the former and 53.5 million of the latter. Release

> Lundbeck reported a 37 percent boost in third-quarter profits to about $170 million, excluding the one-time payment from Takeda Pharmaceutical on the commencement of their co-development deal. Release

> Orion is suing Sun Pharmaceuticals to protect its patent on Stalevo, a treatment for Parkinson's Disease. Report

> OraSure Technologies, which makes diagnostics for HIV and drug use, announced it has settled a patent infringement suit against Schering-Plough. Release

> A recent trial run by BioCryst was negatively impacted by short needles and fat arms. Report

> Sanofi Pasteur is buying into Acambis' program for a novel West Nile vaccine. Report

> Synta Pharmaceuticals' new, $1 billion pact with GlaxoSmithKline for the cancer drug elesclomol (code named STA-4783) is expected to open a spigot of cash for the drug developer. Report

> Nektar Therapeutics got a consolation prize of $135 million from Pfizer--and a fresh shot at signing a new partner--to calm any upset feelings about Pfizer's abandonment of Exubera. Report

And Finally... Book 'em, Danno. A Wyeth sales rep was arrested yesterday for allegedly stealing drug samples and reselling them to pharmacies at a discount. Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.